Medication economic burden of antidepressant non-adherence in Spain
Introduction: Non-adherence to antidepressants is associated with worse disease outcomes (morbidity and mortality) and correlates with higher healthcare resource utilization and costs.Methods: A population-based registry study was conducted to assess non-adherence and to analyze the economic burden...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1266034/full |
| _version_ | 1827762753869185024 |
|---|---|
| author | Eduardo Gutiérrez-Abejón Eduardo Gutiérrez-Abejón Eduardo Gutiérrez-Abejón Eduardo Gutiérrez-Abejón M. Aránzazu Pedrosa-Naudín Diego Fernández-Lázaro Diego Fernández-Lázaro F. Javier Alvarez F. Javier Alvarez |
| author_facet | Eduardo Gutiérrez-Abejón Eduardo Gutiérrez-Abejón Eduardo Gutiérrez-Abejón Eduardo Gutiérrez-Abejón M. Aránzazu Pedrosa-Naudín Diego Fernández-Lázaro Diego Fernández-Lázaro F. Javier Alvarez F. Javier Alvarez |
| author_sort | Eduardo Gutiérrez-Abejón |
| collection | DOAJ |
| description | Introduction: Non-adherence to antidepressants is associated with worse disease outcomes (morbidity and mortality) and correlates with higher healthcare resource utilization and costs.Methods: A population-based registry study was conducted to assess non-adherence and to analyze the economic burden of treatment and from non-adherence to antidepressants in 2021. Non-adherence was measured by the Medication Possession Ratio and those below 80% were classified as non-adherent.Results: In 2021, 246,718 patients (10.60% [95% CI: 10.48–10.72]) received antidepressants at a cost of €29 million. The median antidepressant cost per patient/year was €70.08€, ranging from €7.58 for amitriptyline to €396.66 for agomelatine. Out-of-pocket costs represented 6.09% of total expenditures, with a median copayment of €2.78 per patient. The 19.87% [95% CI 19.52–20.22)] of patients were non-adherent to antidepressants, costing €3.9 million (13.30% of total antidepressant costs). Non-adherence rates exceeded 20% for the tricyclic antidepressants, fluoxetine (23.53%), fluvoxamine (22.42%), and vortioxetine (20.58%). Venlafaxine (14.64%) and citalopram (14.88%) had the lowest non-adherence rates, of less than 15%. The median cost of non-adherent medications per patient/year was €18.96 and ranged from €2.50 (amitriptyline) to €133.42 (agomelatine).Conclusion: Reducing non-adherence to antidepressants is critical to improving clinical and economic outcomes. The implementation of interventions and standardized measures, including early detection indicators, is urgently needed. Antidepressants differ with regard to non-adherence and their cost, and this should be considered when prescribing this medication. The Medication Possession Ratio could be used by the healthcare provider and clinician to identify non-adherent patients for monitoring, and to take necessary corrective actions. |
| first_indexed | 2024-03-11T10:36:59Z |
| format | Article |
| id | doaj.art-e57a5a698a9b47c0927ce22d0bbab00d |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-11T10:36:59Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-e57a5a698a9b47c0927ce22d0bbab00d2023-11-14T10:52:36ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-11-011410.3389/fphar.2023.12660341266034Medication economic burden of antidepressant non-adherence in SpainEduardo Gutiérrez-Abejón0Eduardo Gutiérrez-Abejón1Eduardo Gutiérrez-Abejón2Eduardo Gutiérrez-Abejón3M. Aránzazu Pedrosa-Naudín4Diego Fernández-Lázaro5Diego Fernández-Lázaro6F. Javier Alvarez7F. Javier Alvarez8Pharmacological Big Data Laboratory, Department of Cell Biology, Genetics, Histology and Pharmacology, Faculty of Medicine, University of Valladolid, Valladolid, SpainValladolid Este Primary Care Department, Valladolid, SpainPharmacy Directorate, Castilla y León Health Council, Valladolid, SpainFacultad de Empresa y Comunicación, Universidad Internacional de la Rioja (UNIR), Logroño, SpainPharmacy Directorate, Castilla y León Health Council, Valladolid, SpainDepartment of Cellular Biology, Genetics, Histology and Pharmacology, Faculty of Health Sciences, Campus of Soria, University of Valladolid, Soria, SpainNeurobiology Research Group, Faculty of Medicine, University of Valladolid, Valladolid, SpainPharmacological Big Data Laboratory, Department of Cell Biology, Genetics, Histology and Pharmacology, Faculty of Medicine, University of Valladolid, Valladolid, SpainCEIm, Hospital Clínico Universitario de Valladolid, Valladolid, SpainIntroduction: Non-adherence to antidepressants is associated with worse disease outcomes (morbidity and mortality) and correlates with higher healthcare resource utilization and costs.Methods: A population-based registry study was conducted to assess non-adherence and to analyze the economic burden of treatment and from non-adherence to antidepressants in 2021. Non-adherence was measured by the Medication Possession Ratio and those below 80% were classified as non-adherent.Results: In 2021, 246,718 patients (10.60% [95% CI: 10.48–10.72]) received antidepressants at a cost of €29 million. The median antidepressant cost per patient/year was €70.08€, ranging from €7.58 for amitriptyline to €396.66 for agomelatine. Out-of-pocket costs represented 6.09% of total expenditures, with a median copayment of €2.78 per patient. The 19.87% [95% CI 19.52–20.22)] of patients were non-adherent to antidepressants, costing €3.9 million (13.30% of total antidepressant costs). Non-adherence rates exceeded 20% for the tricyclic antidepressants, fluoxetine (23.53%), fluvoxamine (22.42%), and vortioxetine (20.58%). Venlafaxine (14.64%) and citalopram (14.88%) had the lowest non-adherence rates, of less than 15%. The median cost of non-adherent medications per patient/year was €18.96 and ranged from €2.50 (amitriptyline) to €133.42 (agomelatine).Conclusion: Reducing non-adherence to antidepressants is critical to improving clinical and economic outcomes. The implementation of interventions and standardized measures, including early detection indicators, is urgently needed. Antidepressants differ with regard to non-adherence and their cost, and this should be considered when prescribing this medication. The Medication Possession Ratio could be used by the healthcare provider and clinician to identify non-adherent patients for monitoring, and to take necessary corrective actions.https://www.frontiersin.org/articles/10.3389/fphar.2023.1266034/fullantidepressantmedication adherencedrug utilizationdepressionanxietymental disorders |
| spellingShingle | Eduardo Gutiérrez-Abejón Eduardo Gutiérrez-Abejón Eduardo Gutiérrez-Abejón Eduardo Gutiérrez-Abejón M. Aránzazu Pedrosa-Naudín Diego Fernández-Lázaro Diego Fernández-Lázaro F. Javier Alvarez F. Javier Alvarez Medication economic burden of antidepressant non-adherence in Spain Frontiers in Pharmacology antidepressant medication adherence drug utilization depression anxiety mental disorders |
| title | Medication economic burden of antidepressant non-adherence in Spain |
| title_full | Medication economic burden of antidepressant non-adherence in Spain |
| title_fullStr | Medication economic burden of antidepressant non-adherence in Spain |
| title_full_unstemmed | Medication economic burden of antidepressant non-adherence in Spain |
| title_short | Medication economic burden of antidepressant non-adherence in Spain |
| title_sort | medication economic burden of antidepressant non adherence in spain |
| topic | antidepressant medication adherence drug utilization depression anxiety mental disorders |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1266034/full |
| work_keys_str_mv | AT eduardogutierrezabejon medicationeconomicburdenofantidepressantnonadherenceinspain AT eduardogutierrezabejon medicationeconomicburdenofantidepressantnonadherenceinspain AT eduardogutierrezabejon medicationeconomicburdenofantidepressantnonadherenceinspain AT eduardogutierrezabejon medicationeconomicburdenofantidepressantnonadherenceinspain AT maranzazupedrosanaudin medicationeconomicburdenofantidepressantnonadherenceinspain AT diegofernandezlazaro medicationeconomicburdenofantidepressantnonadherenceinspain AT diegofernandezlazaro medicationeconomicburdenofantidepressantnonadherenceinspain AT fjavieralvarez medicationeconomicburdenofantidepressantnonadherenceinspain AT fjavieralvarez medicationeconomicburdenofantidepressantnonadherenceinspain |